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Leprosy is a chronic disease caused by Mycobacterium leprae and aﬀects the skin and the peripheral nervous system.
Butyrylcholinesterase is coded by the BCHE gene, and the atypical allele (70G; rs1799807) has been investigated as a leprosy risk
factor, with conﬂicting results. The present study estimated the frequencies of variants of rs1799807 and of ﬁve additional SNPs
at the BCHE gene or near it: rs1126680, rs1803274, rs2863381, rs4440084, and rs4387996. A total of 167 patients and 150 healthy
controls were genotyped by TaqMan PCR. Signiﬁcantly higher allelic (70G) and genotypic (70DG) frequencies in rs1799807 were
found in the patient group, with odds ratio (OR) of 6.33 (1.40 to 28.53) for the heterozygote. This ﬁnding was replicated in a
comparison of the cases against a control group of 361 blood donors. The present data suggest that the atypical BChE variant may
predispose to leprosy per se.
1.Introduction
Leprosy is a granulomatous, chronic infectious disease that,
in spite of its ancient origin, still aﬀects thousands of
people around the globe. It is caused by the Gram-negative
bacteriaMycobacterium leprae andinjurespredominantlythe
skin and the peripheral nervous system, leading to sensory
loss in the skin, muscle weakness, and, often, hand and
foot permanent disabilities. The WHO classiﬁes leprosy
in two clinically distinct groups: paucibacillary leprosy,
characterized by ﬁve or fewer skin lesions and negative bacil-
loscopy, and multibacillary leprosy, which includes patients
with six or more skin lesions and positive bacilloscopy.
Individuals with the paucibacillary form usually present a
strongcell-mediatedresponse(Th1type),activatingNKcells
and macrophages that provide a more eﬃcient response
against the bacteria. Individuals with multibacillary lep-
rosy show humoral response (Th2 type), which suppresses
macrophages, increasing the chances of systemic infection
[1, 2].
Thegeneticbackgroundofthehostinﬂuencesthetypeof
damagecaused by the immune responses against an etiologic
agent. It is well known that leprosy is a complex disease with
still unknown environmental and genetic risk factors. Many
candidate genes concerned with susceptibility to infection
per se, clinical manifestation, and reversal reaction have been
studied to date, such as non-MHC genes VDR (12q13.11)
[3]; NRAMP1 (2q35) [4, 5], TLR2 (4q32) [6], PARK2, and
PACRG (6q25-q26) [7], and MHC genes DQB1, DQA1,
DRB1 [8], MICA [9], TNFA [10], and C4B [11]. In the
present study, the candidate is the BCHE gene that codes for
butyrylcholinesterase.
Human butyrylcholinesterase (BChE; EC 3.1.1.8; OMIM
177400) is a serum enzyme produced by the liver that
hydrolyses esters of choline and other esters. BChE has
been associated with lipid metabolism and xenobiotics
detoxiﬁcation [12, 13]. More than 70 variants of the BCHE
gene, located at chromosomal region 3q26.1-q26.2, have
already been described [14]. The atypical variant 70G (209
A>G , rs1799807) codes for a BChE resistant to the2 Journal of Tropical Medicine
hydrolysis of the muscle relaxant succinylcholine and may
cause prolonged apnea after its administration [15]. Thomas
et al. [16], based on the observation that some patients with
leprosy presented prolonged apnea after the administration
of succinylcholine, searched for a relationship between
leprosy and BChE and showed association of the atypical
BChE variant (70G) with this disease. However, data on this
association are controversial: signiﬁcantly higher frequencies
of 70G in patients when compared to controls were found
again [17], whereas other studies failed to replicate this result
[18, 19], possibly due to the lack of accuracy of the enzyme
inhibition method of phenotyping. Here, we present results
of an association study between leprosy and BCHE variants,
including 70G, characterized by DNA genotyping.
2.MaterialsandMethods
2.1. Samples. A case-control approach was applied, includ-
ing 167 nonconsanguineous patients and two independent
control samples: the ﬁrst was composed of 150 healthy
individuals (contact controls) reporting previous history of
exposure to leprosy through current or past cohabitation
with leprosy aﬀected individuals and no consanguinity with
patients; the second control group was composed of blood
donors recruited from the same geographic area and ethnic
background as the cases. Patients were classiﬁed according
to the WHO criteria [1]: 116 with multibacillary and 51
with paucibacillary leprosy. Patients and contact controls
are from the Brazilian state of Paran´ a, being predominantly
from Caucasian origin (76.3 ± 3.5%; 68.0 ± 3.8%, resp.),
representing the ethnic distribution of this state. The control
group of male Euro-Brazilian blood donors (age range
between 18 to 30 years) was described elsewhere [20] and is
the only Brazilian population sample with BCHE SNPs data
determined by DNA analysis.
2.2. Laboratory Methods. DNA was extracted from whole
blood by salting out [21] .T a gS N P sw e r es e l e c t e df r o m
the HapMap Project website (http://www.hapmap.org), each
representing a diﬀerent bin of linkage disequilibrium and
havingaminimumallelefrequency(MAF)of5%intheCau-
casian samples. Following this criterion, two SNPs upstream
(rs2863381 and rs4440084), three intragenic (rs1126680,
G–116A; rs1799807, D70G; rs1803274, A539T), and one
downstream the BCHE gene (rs4387996) were selected for
genotyping.
Genotyping was performed by ﬂuorescence-based allelic
discrimination as implemented in the ABI 7500 TaqMan
platform. A 10μL solution containing 1.5μLo fD N A
solution (20ng/μL), 0.3μL of the TaqMan genotyping kit,
5.0μL of TaqMan universal PCR Master Mix, and 3.2μLo f
ultrapure water was submitted to PCR (45 cycles at 50◦Cf o r
2min,95◦Cfor10min,95◦Cfor15secsofdenaturation,and
60◦C for 1min of hybridization and extension).
SNP rs1803274 (A539T) was also genotyped by PCR-
SSCA for quality control. This SNP was ampliﬁed by PCR
(35 cycles at 94◦C, 48◦C, and 72◦C for 1min each; ﬁnal
extension at 72◦C for 10min): 1μL of DNA (about 100ng),
9μL of PCR super MIX (Invitrogen), and 10pmol of each
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Figure 1: Values of r2 (%) obtained from Haploview for pairs
of the studied SNPs in the total sample of patients plus contact
controls: rs4387996 downstream the BCHE gene (1); rs1126680 (2),
rs1799807 (3), and rs1803274 (4) in the BCHE gene; rs4440084 (5)
and rs2863381 (6) upstream the BCHE gene.
primer (P45 and P43 [22]). A volume of 10μLo fP C R
product was added to 10μL of the denaturation solution
(95% formamide, 0.25% bromophenol blue, 0.25% xylene
cyanole, 10mM EDTA, and 10mM NaOH), submitted to
94◦C (5min), and kept chilled on ice until application in a
polyacrylamide gel (8%), followed by silver nitrate staining
[23].
2.3. Statistical Analysis. Frequency distributions, means ±
standard errors, t-tests, and χ2 tests were calculated using
Statistica for Windows (Statsoft, Inc., 2000; http://www
.statsoft.com). Arlequin 3.0 [24] was used to test for the
Hardy-Weinberg equilibrium (HWE) and for estimating
haplotype frequencies by maximum likelihood, using an
expectation-maximization (EM) algorithm for genotypic
data with unknown gametic phase. Linkage disequilibrium
(LD) was estimated by the r2 parameter as implemented
in Haploview 4.2 [25]. Odds ratios were also calculated
[26]. SPSS 13.0 for Windows (IBM; SPSS Inc., 1989–2004;
http://www.spss.com) was used for forward (Wald) stepwise
multiple logistic regression analyses. Bonferroni’s correction
for multiple testing was used to adjust P values, when
necessary.
3. Results and Discussion
All markers were in HWE in patient and contact control
samples.Figure 1showspairwiser2 estimatesofLDforallsix
studied SNPs in the samples of patients and contact controls;
highest r2 value was 26%, conﬁrming independence of all
tag SNPs genotyped in this study. Table 1 shows frequency
distributions of allele and genotype data for all tag SNPs.
Signiﬁcantstatisticaldiﬀerenceswerefoundbetweenpatients
and contact controls for genotypic (χ2 = 6.05; P = 0.014)
and allelic (χ2 = 5.90; P = 0.015) frequency distributions
of SNP rs1799807: 7.88 ± 2.10% of heterozygotes (70DG)
and 3.94 ± 1.01% of the 70G allele in patients; 1.33 ± 0.94%
of heterozygotes and 0.67 ± 0.57% of the 70G allele in
contact controls. The odds ratio (OR) was 6.33 (CI(95%)
from 1.40 to 28.53) for the 70DG heterozygote. Pauci and
multibacillary patients did not diﬀer on 70G or 70DGJournal of Tropical Medicine 3
Table 1: Frequency distributions of allele and genotype data for the six studied SNPs in patients (M:m u l t i b a c i l l a r y ;P: paucibacillary) and
contact controls, as indicated by the nucleotide base.
SNPa Sample (n) Genotypes (%) Alleles (%)
rs2863381 TT TC CC T C
Patients (161) 58.39 ±3.88 34.16 ±3.74 7.45 ±2.07 75.47 ±2.41 24.73 ±2.41
M (111) 62.16 ±4.60 30.63 ±4.38 7.21 ±2.45 77.48 ±2.82 22.52 ±2.82
P (50) 50.00 ±7.07 42.00 ±6.98 8.00 ±3.84 71.00 ±4.53 29.00 ±4.53
Controls (143) 44.06 ±4.15 49.65 ±4.18 6.29 ±2.03 68.88 ±2.73 31.12 ±2.73
rs4440084 GG GC CC G C
Patients (157) 36.31 ±3.84 49.68 ±3.99 14.01 ±2.77 61.15 ±2.75 38.85 ±2.75
M (107) 37.38 ±4.67 44.86 ±4.81 17.76 ±3.69 59.81 ±3.35 40.19 ±3.35
P (50) 34.00 ±6.70 60.00 ±6.93 6.00 ±3.36 64.00 ±4.80 36.00 ±4.80
Controls (146) 33.56 ±3.91 52.74 ±4.13 13.70 ±2.85 59.93 ±2.87 40.07 ±2.87
rs1126680 GG GA AA G A
Patients (163) 86.50 ±2.68 13.50 ±2.68 0.00 ±0.00 93.25 ±1.41 6.75 ±1.41
M (113) 87.61 ±3.10 12.39 ±3.10 0.00 ±0.00 93.81 ±1.58 6.19 ±1.58
P (50) 84.00 ±5.18 16.00 ±5.18 0.00 ±0.00 92.00 ±2.71 8.00 ±2.71
Controls (142) 86.49 ±2.87 12.16 ±2.74 1.35 ±0.97 92.57 ±1.58 7.43 ±1.58
rs1799807b (D70G) AA AG GG A G
Patients (165) 92.12 ±2.10 7.88 ±2.10 0.00 ±0.00 96.06 ±1.01 3.94 ±1.01
M (114) 92.11 ±2.52 7.89 ±2.52 0.00 ±0.00 96.05 ±1.30 3.95 ±1.30
P (51) 92.16 ±3.76 7.84 ±3.76 0.00 ±0.00 96.08 ±1.94 3.92 ±1.94
Controls (150) 98.67 ±0.94 1.33 ±0.94 0.00 ±0.00 99.33 ±0.57 0.67 ±0.57
rs1803274 (A539T) GG GA AA G A
Patients (163) 67.48 ±3.67 29.45 ±3.57 3.07 ±1.35 82.21 ±2.13 17.79 ±2.13
M (113) 66.37 ±4.44 31.86 ±4.38 1.77 ±1.24 82.30 ±2.56 17.70 ±2.56
P (50) 70.00 ±6.48 24.00 ±6.04 6.00 ±3.36 82.00 ±3.84 18.00 ±3.84
Controls (149) 68.45 ±3.81 28.86 ±3.71 2.68 ±1.32 82.89 ±2.18 17.11 ±2.18
rs4387996 GG GA AA G A
Patients (162) 47.53 ±3.92 45.06 ±3.90 7.41 ±2.06 70.06 ±2.55 29.94 ±2.55
M (112) 47.32 ±4.71 44.64 ±4.70 8.04 ±2.57 69.64 ±3.06 30.36 ±306
P (50) 48.00 ±7.07 46.00 ±7.05 6.00 ±3.36 71.00 ±4.54 29.00 ±4.54
Controls (148) 37.16 ±3.97 48.65 ±4.11 14.19 ±2.86 61.49 ±2.83 38.51 ±2.83
aMost frequent alleles in Caucasians from the HapMap: rs2863381 (T), rs4440084 (G), rs1126680 (G), rs1799807 (A), rs1803274 (G), and rs4387996 (G).
bSigniﬁcant statistical diﬀerences between patients and controls (in bold) for genotype frequencies (P = 0.014; χ2 = 6.05 after the Yates correction) and for
allele distributions (P = 0.015; χ2 = 5.90 after Yates correction).
frequencies, suggesting an impact of this variant over the
early events of interaction between host and pathogen that
result in infection per se, that is, the disease independent
of its clinical form. Based on previous reports [16, 17]
of association of the atypical variant with higher risk of
susceptibility to leprosy, our initial hypothesis was that the
frequency of this variant would be higher in patients than
in controls. In view of this, Bonferroni’s correction was
not used for this case. Statistically signiﬁcant diﬀerence
between patients and contact controls was also found for
allele frequencies of the SNP rs4387996 (Table 1)l o c a t e d
downstreamtheBCHEgene(χ2 =5.07;P = 0.024).However,
this signiﬁcance did not resist Bonferroni’s correction (P>
0.10).
Patients and contact controls diﬀer in sex composition
(χ2 =5.20;P<0.05)andmeanage(t =5.10;P =5.72 ×10−5):
the M/F ratio and mean age of the patients were 1.3 and
55.24±1.37yearsandofthecontrolswere0.8and46.06±1.18
years,respectively.Sincebothgenderandagearewell-known
risk factors for leprosy, these covariables were included, as
independentvariables,inaforwardstepwisemultiplelogistic
regression analysis in which leprosy was the dependent
variable (Table 2). The strategy revealed three signiﬁcant
independentvariables:medianage,SNPrs4387996,andSNP
rs1799807. In the presence of the age eﬀect, association
analysis revealed that the A allele of rs4387996 is protective,
whereas the risk of the 70DG genotype for acquiring leprosy
is 5.18 times higher than that of the 70DD genotype,
conﬁrming our previous analyses. The rs4387996 association
was signiﬁcant in both additive (Table 2, P = 0.021) and
dominantmodelsforalleleA(GGversus GA+AA;P = 0.041;
data not shown).4 Journal of Tropical Medicine
Table 2: Results from a forward stepwise multiple logistic regression in which leprosy (0 = contact control, 1 = patient) was the dependent
variable.
Independent variablesa B ± S.E. Wald df P Odds ratio (95% C.I.)
Median age 0.91 ±0.25 13.03 1 0.000 2.48 (1.51 to 4.05)
SNP rs4387996 −0.45 ±0.20 5.34 1 0.021 0.64 (0.44 to 0.93)
SNP rs1799807 1.64 ±0.79 4.34 1 0.037 5.18 (1.10 to 24.33)
Constant −2.19 ±0.97 5.07 1 0.024 0.11
aMedian age (≤51 = 1, >51 = 2); SNP rs4387996 (GG = 1, GA = 2, AA = 3); SNP rs1799807 (70GG = 1, 70DG = 2). Other independent variables were not
signiﬁcant: rs2863381; rs4440084; rs1126680; rs1803274 and sex.
Table 3: Haplotypea frequencies compared between contact control (C) and patient (P) samples.
SNPsb Samples (%) χ2; P (Bonferroni’s correction)
rs2863381 rs4440084 rs1126680 rs1799807 (D70G) rs1803274
(A539T) rs4387996 C P
TG GA GG 24.9 25.1 n.s.
TG GA GA 12.0 13.8 n.s.
TC GA GG 11.6 18.5 5.28; 0.0216 (0.151)
TC GA GA 9.5 3.4 8.62; 0.0033 (0.023)
CC G A GG 8.9 3.8 6.69; 0.0097 (0.068)
CC G A G A 8.1 6.5 n.s.
CG G A GG 7.1 6.5 n.s.
aSelected on the basis of frequency higher than 5% at least in one of the samples. bMost frequent nucleotides in Caucasians from the HapMap: rs2863381 (T),
rs4440084 (G), rs1126680 (G), rs1799807 (A), rs1803274 (G), and rs4387996 (G).
To conﬁrm the ﬁndings for the 70DG genotype, data
from the case group was compared with genetic information
obtainedpreviouslyforasampleof361Euro-Brazilianblood
donors of Curitiba [20], which presented 3.60% of het-
erozygotes and 1.80% of 70G frequency. Again, statistically
signiﬁcant diﬀerences for genotype (χ2 = 4.45; P<0.05)
and allele (χ2 = 4.36; P<0.05) frequencies were found.
Estimate of OR for this second comparison was 2.29 (CI(95%)
from 1.04 to 5.05). The blood donor sample is appropriated
for comparison, given the similar Euro-Brazilian origin of
the cases, and the result clearly reinforces our hypothesis.
Of note, the OR found in the comparison of cases against
blood donor controls is lower than the one found for cases
against contact controls. This may be due to the selection
criterionforthecontactcontrolthatmayhaveledtoasample
with a higher frequency of individuals presenting innate
resistance to leprosy, as they have more likely been exposed
than the blood donor controls and yet did not develop
the disease. Furthermore, the contact controls report no
consanguinity with any leprosy patient. Unfortunately, DNA
data of the blood donor control group were not available
for marker rs4387996, also associated with leprosy in the
primary comparison.
To further advance on the understanding of the impact
of BCHE variants over leprosy susceptibility, we performed a
haplotypic analysis, involving all haplotypes with frequency
> 5% in at least one of the samples (Table 3). Signiﬁcantly
higher frequency of the [T; C; G; A; G; A] haplotype was
found in contact controls when compared to cases (P =
0.023 after Bonferroni’s correction, OR = 0.34; CI(95%) from
0.16 to 0.72). Although genotypes were of unknown phase
and haplotype frequencies had to be estimated [24], the
frequencies of this haplotype are expected to be rather
accurate, considering that the EM algorithm usually presents
very reliable performances for haplotype estimation [27].
Furthermore, both the total number of gametes (contact
controls: 268; patients: 297) and the estimated haplotype
numbers for contact controls (N = 25) and patients (N =
10) reinforce the accuracy of this frequency inference.
This protective haplotype diﬀers from the most frequent
one observed among cases ([T; G; G; A; G; G], 25.07%)
only at positions corresponding to SNPs rs4440084 and
rs4387996.Thesetwovariants(C;A)arefoundintheciscon-
formationin10.92%andin18.86%ofhaplotypesinpatients
and contact controls, respectively (χ2 = 8.93; P = 0.003).
T h eO Rv a l u ef o rt h i sc o m p a r i s o ni s0 . 4 9( C I (95%) 0.30–
0.79) and may indicate a protective eﬀect that is two times
higher than that of the haplotypes-bearing variants G and
G in these respective SNPs. Considering that the rs4440084
SNP was not signiﬁcant in the regression analysis (Table 2),
it is possible that the protective eﬀect of this haplotype is
only due to the A variant of SNP rs4387996. However, the
SNP independent variables in the regression analyses were
the genotypes, as haplotypes were not known individually.
If the present data referring to the atypical variant
(70G) is not due to linkage disequilibrium with other causal
genetic variants, it is possible that the atypical variant of
BChE may predispose to leprosy, although the physiological
mechanism remains unclear. One possible hypothesis would
be a relation of 70G with the acetylcholine- (ACh-) mediated
immune response. Activated leucocytes release small quan-
tities of ACh [28], which acts like autocrine and paracrineJournal of Tropical Medicine 5
signaling factors, mediating the contact with target cells.
M o r e o v e r ,w h e nA C hi sp r o d u c e d ,i ta c t sa sp a r to fa n
anti-inﬂammatory parasympathetic reaction, inhibiting the
nuclear action of NF-κB and stopping the production of
proinﬂammatory citokynes as TNF, IL-1, IL-6, IL-8, and
HMGB1, leading to the interruption of the inﬂammatory
process [29]. Therefore, high levels of ACh are likely to
cause a decrease in the inﬂammatory response. It is possible
to speculate that this decrease in the inﬂammatory process
can lead to a less competent host response to M. leprae.
Acetylcholinesterase (AChE) activity is inhibited by excess
of ACh [30]. Once AChE is inhibited, BChE becomes
responsible for ACh hydrolysis [31]. The usual (70D)B C h E
variant is able to accomplish this function, but the atypical
variant (70G), which has less aﬃnity to the ACh substrate,
could interfere in this regulation, failing in reducing ACh
levels, consequently preventing the inﬂammatory response
and contributing to the acquisition of leprosy.
Considering that SNP rs4387996 independently associ-
ated with leprosy in our population sample is intergenic, it
is diﬃcult to infer a functional role. However, one possible
hypothesis is that the variants (G, A) are in linkage disequi-
librium with variants of the SLITRK3 gene located down-
stream the BCHE gene but in the same LD bin. The Slitrk3
protein encoded by this gene is a neuronal transmembrane
protein that controls axons and dendrites outgrowth [32].
The association among BCHE variants and the SLITRK3
gene is unclear, but it is possible that they may be markers
of the inﬂuence of this gene in the neuronal development
which, somehow, can protect the nerves from M. leprae.
The present study reveals two independent signals of
association between leprosy and variants of the BCHE gene,
including the known functional variant 70G (rs1799807),
establishing BCHE as a strong candidate gene for the
control of leprosy susceptibility. It is not clear whether the
associationofthe70Gvariantwithleprosyisreallyfunctional
or is due to linkage disequilibrium with a variant of another,
unknown gene. However, it is valid to suppose that the
functional impact of this SNP that can lead to a less eﬃcient
BChE may predispose to the disease by failing to degrade a
supposedsubstrate,suchasacetylcholine,wheneveritshould
act upon it. This fact could disturb the immune response
when mediated by acetylcholine, reducing the inﬂammatory
process and increasing the susceptibility to leprosy.
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